Hereditary angioedema (HAE) is a rare genetic disease caused by mutations in the SERPING1 gene, leading to deficiency of C1 inhibitor and episodic attacks of severe subcutaneous and submucosal swelling — attacks that can be life-threatening when they affect the larynx. For decades, management required either acute treatment (C1 inhibitor concentrate, icatibant, ecallantide) or chronic prophylaxis with subcutaneous or IV infusions every 1–4 weeks. In 2026, CRISPR gene editing has produced results suggesting patients may need none of that — ever again.
The Target: Plasma Kallikrein
NTLA-2002 (Intellia Therapeutics / Regeneron) uses lipid nanoparticle-delivered CRISPR-Cas9 to edit the KLKB1 gene in hepatocytes, permanently reducing production of plasma prekallikrein — the enzyme upstream of the bradykinin pathway that drives HAE attacks. By reducing prekallikrein production, the drug breaks the chain of events leading to swelling attacks, regardless of which mutation the patient carries.
The elegance of the approach is that the edit targets prekallikrein rather than upstream C1 inhibitor: even in C1 inhibitor-deficient patients, eliminating enough prekallikrein eliminates attacks. And because liver cells do not regenerate significantly, the edit is permanent — one injection, lifelong benefit.
Phase III Results: HAELO Trial
The Phase III HAELO trial enrolled 90 patients with confirmed HAE type I or II who had ≥3 attacks in the prior 12 months. Patients received a single IV infusion of NTLA-2002 at 75 mg:
- Primary endpoint: 95% mean reduction in HAE attack rate vs run-in period at Month 3–12.
- Attack-free patients: 72% of patients experienced zero attacks in months 3–12 post-treatment.
- Plasma prekallikrein reduction: Mean 85% reduction sustained at 12 months.
- Safety: No serious adverse events attributed to the gene editing; no off-target edits detected by whole-genome sequencing in liver biopsy samples from a subset of participants.
These results dramatically outperform the best chronic prophylactic agents currently available. Garadacimab (a monoclonal anti-Factor XIIa antibody, approved 2023) and donidalorsen (oral plasma kallikrein inhibitor) reduce attack rates by 80–90% but require ongoing monthly or twice-daily dosing. NTLA-2002 appears to exceed both in efficacy and deliver it durably without chronic treatment burden.
The Broader Significance for CRISPR Medicine
NTLA-2002 follows Intellia's earlier success with NTLA-2001 (in vivo CRISPR editing for transthyretin amyloidosis), which received FDA approval in 2024. Together, these programs establish that lipid nanoparticle delivery of CRISPR-Cas9 to the liver is safe, effective, and — crucially — permanent with a single treatment. This is the in vivo gene editing playbook working as designed.
The implications extend to every hepatocyte-expressed gene involved in disease. The liver produces clotting factors, lipoproteins, complement proteins, acute phase reactants, and numerous circulating hormones. Diseases potentially addressable with the same LNP-CRISPR approach include hemophilia A and B, familial hypercholesterolemia, alpha-1 antitrypsin deficiency, and primary hyperoxaluria — all of which have active CRISPR programs in various clinical stages.
Regulatory Status and Access
Intellia submitted a BLA for NTLA-2002 in Q1 2026. The FDA granted Priority Review with a PDUFA date in Q4 2026. If approved, it would become the second FDA-approved in vivo CRISPR therapy, and the first one-time cure for HAE. Pricing discussions are ongoing, with analysts projecting a list price in the $3–4 million range — consistent with other one-time gene therapies and reflecting the lifetime cost offset of eliminating chronic prophylaxis.
Conclusion
CRISPR for HAE is one of the most compelling demonstrations yet that the gene editing revolution is real and arriving ahead of schedule. For the estimated 1 in 50,000 people living with HAE globally — and the 50% who remain undiagnosed — a one-time cure would transform a life structured around attack prevention into one structured around everything else. Healthcare facilities can find relevant diagnostic equipment in our catalog.
